A k JLXG _ U 3 > 0 ASAHI GLASS CO., LTD March 19, 2003 WEUM12P.sSa0A.s0.MhEEPinanaergvsnyttino,rDosnMyno,lmamDviaClmenCni2itaoaa0kdl4Ae6Pv70re0on4tue5ceMt,iNonWAgency fl i l ,, , - f .

fiR S - IA 3U - RECEIVED OFFr-I'CcnE-TPO?

ff NORTHERN KENTUCKY OFFICE SUITE 340 1717 DIXIE HIGHWAY COVINGTON, KENTUCKY41011-4704 606-331-2838 513-381-2838 FAX: 513-381-6613 DAYTON, OHIO OFFICE SUITE 900 110 NORTH MAIN STREET DAYTON, OHIO 45402-1786 937-228-2838 FAX: 937-228-2816 TAFT, STETTINIUS & HOLLISTER LLP 425 WALNUT STREET, SUITE 1800 CINCINNATI, OHIO 45202-3957 513-381-2838 FAX: 513-381-0205 www.taftlaw.com CLEVELAND, OHIO OFFICE 3500 BP TOWER 200 PUBLIC SQUARE CLEVELAND, OHIO 44114-2302 216-241-2838 FAX: 216-241-3707 COLUMBUS, OHIO OFFICE 21 EAST STATE STREET COLUMBUS, OHIO 43215-4221 614-221-2838 FAX:614-221-2007 Ro b er ta .

AR226-1486 ENVIRONMENTAL AND HEALTH ASSESSMENT OF PERFLUOROOCTANE SULFONIC ACID AND ITS SALTS August 20, 2003 Prepared by 3M in consultation with Jack Moore, D.V.M., DABT, Hollyhouse, Inc.

DuPont itooratorv `EorrntTenot*ic0a9t4ogvP90f48i0nd15us0tri Mtdic ' Nwrt. 06 197U-0050 D uPont H askell Laboratory A t 2 2 L -1 o o o p c ^ J -- < ~> c> -0c> ( 3 ?

From: Bernard J f t * * 1*13/2001 12:04 PM To rHty_bni^ftu*l4 oorn cc: jmstagwifminfllenbustcom, wpiaOthbfoliogreup.com, nnroillyObailattantic.nt Subject Oct 13 Hi Bam, Wonderful day coming weathertze, It is nearly noon, I am trying to get stuff moved off my desk, been real busy lately, so barely able to triage the paper, some gets tossed without a look, som e must be dealt with on the spot, and the other third needs attention so just piles up.

3M General Offices >p 3M March 17, 2000 3M Center St.

Final Draft Guidance Document Telomer Research Program (TRP) AR226-1888 Guidance Document Best Analytical Practices for TRP Studies Author Marilyn Stadalius Critical Path Services 300 Foulk Road, Suite 1C Wilmington, Delaware 19803 Completion Date March 2004 RECEIVED OPPT NCIC 2004 DEC 22 AM 11:20 Sponsor Telomer Research Program Asahi Glass Co., Ltd.

AR226-2306 Charles J Zarzecki ' 03/03/2003 01:16 PM To: Catherine A Barton/AE/DuPont cc: Subject: Re: C8 meeting Q Cathy, Yes, they can be done, however, not until Wednesday as I am on m y way out the door to Front Royal.

AR226-2320 Ann K Masse 04/02/2003 06:03 PM To: Irene A Legiec/AE/DuPont@DuPont, Mark D Richmond/AE/DuPont@DuPont cc: Catherine A Barton/AE/DuPont@DuPont Subject: Dispersion modeling data folks, W e need to have this data to Cathy by the end of next week (4/11).

AR226-2323 / Irene A Legiec 04/03/2003 10:40 AM To: Ann K Masse/HO/DuPont@DuPont cc: Mark D Richmond/AE/DuPont@DuPont, Catherine A Barton/AE/DuPont@DuPont, Richard S Viekery/AE/DuPont@DuPont, Maria S Angelo/AE/DuPont@DuPont, Paul J Gorzsas/ABDuPont@DuPont Subject Re: Dispersion modeling data Q Ann, W e have a ballpark number for influent data.

AR226-2359 J DRAFT PHASE II QUALITY ASSURANCE PROJECT PLAN DUPONT WASHINGTON WORKS SITE WASHINGTON, WEST VIRGINIA ) Date: March 2004 Project No.: 507532 18983990.04006 ||S |) 'i l i r CORPORATE REMEDIATION GROUP An Alliance between DuPont and URS Diamond Barley Mill Plaza, Building 27 Wilmington, Delaware 19805 EXP000431 Draft Document Do Not Gite or Quote, March 30, 2004 Draft Phase II Quality Assurance Project Plan Table of Contents TABLE OF CONTENTS 1.0 Project Management........................................................... ........................................ 1 1.1 Project Background...............................................................................................1 1.2 Project Description..............................................................................................2 1.3 Project Organization............................................................................................. 3 1.3.1 Project Director..................................................................................... 3 1.3.2 Project Manager.............................................................. 4 1.3.3 Health and Safety Officer........................................ 4 1.3.4 Project Geologist..................................................... 4 1.3.5 Technical Consultants............................................................................ 4 1.3.6 Technical and Support Staff.................................................................. 4 1.3.7 Quality Assurance Officer.................................................. 5 1.3.8 Project Chemist................... !.........................................................

-'Vi cenerai osnees 3M Gemer 6S5t.!

RECEIVED irrt cno OfrJUL-5 AHII: 22 AK 2Z _ 373Z Self-Reported Medical Conditions in Perfluorooctanesulfonyl Fluoride Manufacturing Workers Final Report Bruce H.

ATSttCn:A SDeocctuiomne8n(et)P/FroYcIessing Center Attachment 1 P-1 P-1 July 28,2006 Page 4 of 5 M Z26 _373J- Acronym codefor Tables 1 and 2 In Tables 1 and 2, the following acronyms are used: acronym meaning CW FW WW DuPont Chambers Works facility in Deepwater, New Jersey DuPont Fayetteville Works facility in Fayetteville, North Carolina DuPont Washington Works facility in Parkersburg, West Virginia PPPFFFHPBeAxAA PFHpA PPPPFFFFOUDNnAAAA PFDoA PFBS PPPFFFOHOSxSSA PPeerrfflluuoorroobpuentatannooicicaacicdid Perfluorohexanoic acid Perfluoroheptanoic acid Perfluorooctanoic acid Perfluorononanoic acid Perfluorodecanoic acid Perfluorotmdecanoic acid PPPeeerrrfffllluuuooorrrooobhdueoxtdaaennceaenssuoulilfcfooanncaaitdtee Perfluorooctane sulfonate Perfluorooctane sulfonamide Attachment 1 Spaed Matrix Lab Blank 1 cw # P % cw p 3 cw n m 34 CW (DUPLICATE) c w v 5 cw i cw < P * CW 7 cw qp ( CW WG18817-102 Y2 WG18817-101 Y1 L8789-1 Y1 LB789-2 Y1 L87B9-3 Y1 WG18817-103Y1 L8789-4 Y1 L8789-5 Y1 LB789-5 Y1 LB789-6 Y1 L8789-7 Y1 L8789-8 Y1 % Recovery ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL WQ18817 W Q 18817 WQ18817 WQ18817 WG18817 WG18817 WG18817 WG18817 WG18817 WG18817 WG18817 WG18817 PFBA 81.2 ND ND ND ND ND ND <1.44 <1.44 <1.44 NO ND PFPeA 79.0 ND ND ND ND ND ND ND NO ND ND ND PFHxA 85.8 ND 1.82 ND <0.900 <0.900 ND ND ND <0.900 ND <0.900 PFHpA 83.5 ND ND ND ND ND <1.41 3.71 3.71 11.7 6.91 ND PFO A 110 ND 7.71 9.72 24.1 21.6 42.8 13.4 13.4 111 56.7 26.6 PFNA 11B ND 4.28 2.90 7.10 6.78 18.3 4.22 4.22 53.1 29.2 2.37 PFDA 115 ND <1.06 <1.08 1.64 1.51 8.47 1.82 1.82 13.5 7.47 <1.08 PFUnA 128 ND <1.02 <1.02 2.37 2.60 1.70 <1.02 <1.02 3.99 1.55 ND PFDoA 60.9 ND ND ND <0.600 <0 600 0.943 <0.600 <0.600 1.10 0.737 ND PFBS 94.8 ND ND ND ND ND ND ND ND ND ND ND PFHxS 104 ND <3.72 <3.72 39.1 33.5 <3.72 <3.72 <3.72 4.28 <3.72 3.81 PFOS 112 ND 51.1 35.3 68.2 58.0 25.7 35.0 36.0 39.0 53.8 36.8 PFO SA 73.5 ND ND ND ND ND ND ND ND NO ND ND Attachment 1 PFBA PFPeA PFHxA PFHpA PFOA PFNA PFDA PFUnA PFDoA PFBS PFHxS PFOS PFOSA tp // CW ^ k F w t f f lV L8789-9 Y1 LS789-10Y1 L8789-11 Y1 ngftnL ngAnL WG1B817 WG18817 ngAmL WG18817 ND ND NO ND ND ND ND ND ND NO 1.48 ND 12.9 13.0 28.3 <1.53 3.97 2.28 ND <1.08 <1.08 ND <1.02 <1.02 ND ND ND ND ND ND <3.72 <3.72 6.64 30.7 46.9 37.2 ND ND ND t-2.